David Rescott
Stock Analyst at Baird
(3.71)
# 741
Out of 5,143 analysts
80
Total ratings
61.29%
Success rate
6.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Rescott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDT Medtronic | Maintains: Neutral | $103 → $100 | $96.75 | +3.36% | 9 | Feb 18, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $118 → $101 | $75.15 | +34.40% | 10 | Feb 5, 2026 | |
| PEN Penumbra | Downgrades: Neutral | $345 → $374 | $339.59 | +10.13% | 32 | Jan 16, 2026 | |
| SIBN SI-BONE | Maintains: Buy | $21 → $23 | $15.29 | +50.43% | 8 | Dec 18, 2025 | |
| EW Edwards Lifesciences | Maintains: Neutral | $88 → $87 | $82.40 | +5.58% | 7 | Dec 16, 2025 | |
| HAE Haemonetics | Maintains: Outperform | $87 → $99 | $61.68 | +60.51% | 2 | Dec 15, 2025 | |
| LIVN LivaNova | Maintains: Outperform | $63 → $70 | $69.05 | +1.38% | 6 | Nov 13, 2025 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $111 → $110 | $82.43 | +33.45% | 3 | Apr 25, 2025 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $600 → $575 | $494.02 | +16.39% | 3 | Apr 23, 2025 |
Medtronic
Feb 18, 2026
Maintains: Neutral
Price Target: $103 → $100
Current: $96.75
Upside: +3.36%
Boston Scientific
Feb 5, 2026
Maintains: Outperform
Price Target: $118 → $101
Current: $75.15
Upside: +34.40%
Penumbra
Jan 16, 2026
Downgrades: Neutral
Price Target: $345 → $374
Current: $339.59
Upside: +10.13%
SI-BONE
Dec 18, 2025
Maintains: Buy
Price Target: $21 → $23
Current: $15.29
Upside: +50.43%
Edwards Lifesciences
Dec 16, 2025
Maintains: Neutral
Price Target: $88 → $87
Current: $82.40
Upside: +5.58%
Haemonetics
Dec 15, 2025
Maintains: Outperform
Price Target: $87 → $99
Current: $61.68
Upside: +60.51%
LivaNova
Nov 13, 2025
Maintains: Outperform
Price Target: $63 → $70
Current: $69.05
Upside: +1.38%
Merit Medical Systems
Apr 25, 2025
Maintains: Outperform
Price Target: $111 → $110
Current: $82.43
Upside: +33.45%
Intuitive Surgical
Apr 23, 2025
Maintains: Outperform
Price Target: $600 → $575
Current: $494.02
Upside: +16.39%